^
    Back
    Association details:
    Biomarker:NRAS mutation
    Cancer:Melanoma
    Drug:amuvatinib (MP470) (c-KIT inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Melanoma Res
    Title:

    Amuvatinib has cytotoxic effects against NRAS- but not BRAF-mutant melanoma

    Excerpt:
    Increasing concentrations of amuvatinib selectively inhibited the growth of NRAS-mutant, but not BRAF-mutant melanoma cell lines, an effect associated with induction of S-phase and G2/M-phase cell cycle arrest and induction of apoptosis.
    DOI:
    10.1097/CMR.0000000000000103